Exploring the Latest new anti-obesity drugs Deal by EraCal Therapeutics: A Guide to Rapidly Accessing Transaction Insights

On January 24, 2024, Novo Nordisk entered into a potential collaboration and licensing agreement with EraCal Therapeutics to jointly develop a new mechanism of action drug for the control of appetite and body weight.

Under the terms of the agreement, Novo Nordisk has obtained all exclusive rights to develop and commercialize EraCal's oral small molecule drugs for the treatment of obesity; EraCal is expected to receive up to 235 million euros ($255 million) in upfront, development, and commercial milestones payments, as well as royalties on sales after product launch.

The two companies initially came together in January 2022 to collaborate on the research of new anti-obesity drug targets related to the regulation of food intake and other metabolic phenotypes.

About Era-379

The drug Era-379 is a small molecule drug that falls under the therapeutic areas of endocrinology and metabolic disease. Its active indication is obesity, suggesting that it is being developed to address this specific condition. The drug is being developed by EraCal Therapeutics AG, which is the originator organization responsible for its development. Click the image below to directly embark on the exploration journey with the Era-379!

Currently, Era-379 has entered the preclinical stage. Trial results have shown that with just once-daily oral administration of Era-379, obese mice experienced a weight reduction of at least 20% within two weeks.

About EraCal Therapeutics

EraCal Therapeutics was founded in 2018 and is dedicated to the research and development of safe and effective anti-obesity drugs through a zebrafish phenotypic screening platform. The company aims to address the issue of obesity in patients and prevent complications arising from the condition.

The company is a spin-off from research conducted at the University of Zurich and Harvard University, co-founded by Dr. Josua Jordi and Simon Breitler. Dr. Jordi has nearly a decade of research experience in the field of appetite suppressants.

As early as 2019, the company had already completed a seed funding round, raising an amount of 6 million Swiss francs.

How to get the latest progress on drug deals?

If you would like to access the latest transaction event information, you can click on the 'Deal' module from the homepage of the Synapse database. Within the Deal module, you can search for global pharmaceutical transaction information using labels such as Drugs, Organization, Target, Drug Type, Deal Date. 

Furthermore, you can obtain the original link to the transaction coverage by clicking on the "Deal Name."

In the analysis view, you can see the most active assignors, assignees, popular targets, and other dimensions of analysis, as well as the distribution of research and development statuses at the time of the transaction, to help you better understand the search results.

The Synapse database also supports the ability to view current transactions from the dimension of "drugs" (by selecting "drugs" from the "Adjust Dimension" dropdown menu above). Targeting transactions involving renowned pharmaceutical companies that are of interest to the industry, such as Merck, Roche, etc., Synapse has identified a group of "leading companies" through drugs that have achieved global sales exceeding 1 billion US dollars in 2022. Transactions involving drugs from these leading companies can be filtered by clicking on the "Leading Company" tag on the left-hand side.

In addition to the drug transaction module, you can also view related transaction history on the drug detail page and the institution detail page.

Click on the image below to embark on a brand new journey of drug discovery!